XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Service Receivable
Accumulated Other Comprehensive Loss
Accumulated Deficit
Balance, beginning (in shares) at Dec. 31, 2021   716 41,964        
Balance, beginning at Dec. 31, 2021 $ 140,417 $ 1 $ 4 $ 400,503 $ (139) $ (142) $ (259,810)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 1,152     1,152      
Other comprehensive gain (loss) (606)         (606)  
Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)   (328) 1,342        
Issuance of common stock upon conversion of Series E Convertible Preferred Stock (1) $ (1)          
Preferred stock dividend (6)           (6)
Release of clinical trial funding commitment 139       139    
Net loss (10,993)           (10,993)
Balance, ending (in shares) at Mar. 31, 2022   388 43,306        
Balance, ending at Mar. 31, 2022 130,102 $ 0 $ 4 401,655 0 (748) (270,809)
Balance, beginning (in shares) at Dec. 31, 2021   716 41,964        
Balance, beginning at Dec. 31, 2021 140,417 $ 1 $ 4 400,503 (139) (142) (259,810)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (21,436)            
Balance, ending (in shares) at Jun. 30, 2022   388 43,306        
Balance, ending at Jun. 30, 2022 120,474 $ 0 $ 4 402,710 0 (982) (281,258)
Balance, beginning (in shares) at Mar. 31, 2022   388 43,306        
Balance, beginning at Mar. 31, 2022 130,102 $ 0 $ 4 401,655 0 (748) (270,809)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 1,055     1,055      
Other comprehensive gain (loss) (234)         (234)  
Preferred stock dividend (6)           (6)
Net loss (10,443)           (10,443)
Balance, ending (in shares) at Jun. 30, 2022   388 43,306        
Balance, ending at Jun. 30, 2022 120,474 $ 0 $ 4 402,710 $ 0 (982) (281,258)
Balance, beginning (in shares) at Dec. 31, 2022   61 44,677        
Balance, beginning at Dec. 31, 2022 106,343 $ 0 $ 4 404,834   (395) (298,100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 1,064     1,064      
Other comprehensive gain (loss) 319         319  
Net loss (11,223)           (11,223)
Balance, ending (in shares) at Mar. 31, 2023   61 44,677        
Balance, ending at Mar. 31, 2023 96,503 $ 0 $ 4 405,898   (76) (309,323)
Balance, beginning (in shares) at Dec. 31, 2022   61 44,677        
Balance, beginning at Dec. 31, 2022 106,343 $ 0 $ 4 404,834   (395) (298,100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (22,373)            
Balance, ending (in shares) at Jun. 30, 2023   61 44,677        
Balance, ending at Jun. 30, 2023 86,579 $ 0 $ 4 407,479   (431) (320,473)
Balance, beginning (in shares) at Mar. 31, 2023   61 44,677        
Balance, beginning at Mar. 31, 2023 96,503 $ 0 $ 4 405,898   (76) (309,323)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 1,581     1,581      
Other comprehensive gain (loss) (355)         (355)  
Net loss (11,150)           (11,150)
Balance, ending (in shares) at Jun. 30, 2023   61 44,677        
Balance, ending at Jun. 30, 2023 $ 86,579 $ 0 $ 4 $ 407,479   $ (431) $ (320,473)